ISIS EIF4E Rx

DRUG2 trials

Sponsors

Ionis Pharmaceuticals, Inc.

Conditions

Castrate-Resistant Prostate CancerNon-small Cell Lung Cancer

Phase 1

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

CompletedNCT01234025

Ionis Pharmaceuticals, Inc.Castrate-Resistant Prostate Cancer

Start: 2010-11-30End: 2013-12-31Updated: 2023-10-06

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel

CompletedNCT01234038

Ionis Pharmaceuticals, Inc.Non-small Cell Lung Cancer

Start: 2010-11-30End: 2013-01-31Updated: 2018-06-27